No, that article has one paragraph which frets that if Medicare drives down drug prices in the USA, pharma companies might cut R&D spending, and might get less new drugs (note the conditional and hypothetical). A colleague in biomedical research says that its just a common misconception that R&D costs drive drug prices eg. https://doi.org/10.1136/bmj-2022-071710